Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
Clinical Trials Arena on MSN
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...
Bengaluru: Researchers at the Indian Institute of Science (IISc) have uncovered how subtle variations in sugar molecules ...
Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...
The devastating retrovirus HTLV-1 has eluded scientists for decades. Overcoming chronic funding and other challenges, ...
ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to ...
In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin ...
As the first COVID-19 vaccines are rolled out around the world, HIV/AIDS experts and advocates have sought to reassure those ...
The two-drug regimen dolutegravir/lamivudine is as effective as the three-drug regimen dolutegravir plus tenofovir ...
Abstract: CD4+ T cells play a crucial role in adaptive immunity and are a significant component of immunological response in many settings. Computational prediction of which antigenic peptides are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback